These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 11127213

  • 1. The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor alpha genotype in early postmenopausal women.
    Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Saarikoski S, Honkanen R, Mäenpää PH.
    J Bone Miner Res; 2000 Dec; 15(12):2479-86. PubMed ID: 11127213
    [Abstract] [Full Text] [Related]

  • 2. Relation of androgen receptor gene polymorphism to bone mineral density and fracture risk in early postmenopausal women during a 5-year randomized hormone replacement therapy trial.
    Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Pallonen H, Saarikoski S, Honkanen R, Mäenpää PH.
    J Bone Miner Res; 2003 Feb; 18(2):319-24. PubMed ID: 12568409
    [Abstract] [Full Text] [Related]

  • 3. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy.
    Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Saarikoski S, Honkanen R, Mäenpää PH.
    J Bone Miner Res; 2000 Feb; 15(2):315-21. PubMed ID: 10703934
    [Abstract] [Full Text] [Related]

  • 4. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A.
    Ann Acad Med Stetin; 2003 Feb; 49():111-30. PubMed ID: 15552843
    [Abstract] [Full Text] [Related]

  • 5. Leucine7 to proline7 polymorphism in prepro-NPY gene and femoral neck bone mineral density in postmenopausal women.
    Heikkinen AM, Niskanen LK, Salmi JA, Koulu M, Pesonen U, Uusitupa MI, Komulainen MH, Tuppurainen MT, Kröger H, Jurvelin J, Saarikoski S.
    Bone; 2004 Sep; 35(3):589-94. PubMed ID: 15336593
    [Abstract] [Full Text] [Related]

  • 6. A common methylenetetrahydrofolate reductase (C677T) polymorphism is associated with low bone mineral density and increased fracture incidence after menopause: longitudinal data from the Danish osteoporosis prevention study.
    Abrahamsen B, Madsen JS, Tofteng CL, Stilgren L, Bladbjerg EM, Kristensen SR, Brixen K, Mosekilde L.
    J Bone Miner Res; 2003 Apr; 18(4):723-9. PubMed ID: 12674333
    [Abstract] [Full Text] [Related]

  • 7. Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen.
    Rapuri PB, Gallagher JC, Knezetic JA, Haynatzka V.
    Maturitas; 2006 Mar 20; 53(4):371-9. PubMed ID: 16139450
    [Abstract] [Full Text] [Related]

  • 8. Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women.
    Salmen T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Pallonen H, Saarikoski S, Honkanen R, Mäenpää PH.
    Ann Med; 2003 Mar 20; 35(4):282-8. PubMed ID: 12846271
    [Abstract] [Full Text] [Related]

  • 9. The role of antiandrogens in hormone replacement therapy.
    Schneider HP.
    Climacteric; 2000 Dec 20; 3 Suppl 2():21-7. PubMed ID: 11379383
    [Abstract] [Full Text] [Related]

  • 10. Relation of estrogen receptor-alpha gene polymorphism and hormone replacement therapy to fall risk and muscle strength in early postmenopausal women.
    Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Saarikoski S, Honkanen R, Partanen J, Mäenpää PH.
    Ann Med; 2002 Dec 20; 34(1):64-72. PubMed ID: 12014437
    [Abstract] [Full Text] [Related]

  • 11. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
    Tuppurainen MT, Komulainen M, Kröger H, Honkanen R, Jurvelin J, Puntila E, Heikkinen AM, Alhava E, Saarikoski S.
    Osteoporos Int; 1998 Dec 20; 8(1):32-8. PubMed ID: 9692075
    [Abstract] [Full Text] [Related]

  • 12. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
    Bagger YZ, Tankó LB, Alexandersen P, Hansen HB, Møllgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C.
    Bone; 2004 Apr 20; 34(4):728-35. PubMed ID: 15050905
    [Abstract] [Full Text] [Related]

  • 13. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
    Barrett-Connor E, Wehren LE, Siris ES, Miller P, Chen YT, Abbott TA, Berger ML, Santora AC, Sherwood LM.
    Menopause; 2003 Apr 20; 10(5):412-9. PubMed ID: 14501602
    [Abstract] [Full Text] [Related]

  • 14. Estrogen receptor alpha and beta polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy?
    Silvestri S, Thomsen AB, Gozzini A, Bagger Y, Christiansen C, Brandi ML.
    Menopause; 2006 Apr 20; 13(3):451-61. PubMed ID: 16735942
    [Abstract] [Full Text] [Related]

  • 15. Does hormone-replacement therapy prevent fractures in early postmenopausal women?
    Randell KM, Honkanen RJ, Kröger H, Saarikoski S.
    J Bone Miner Res; 2002 Mar 20; 17(3):528-33. PubMed ID: 11874244
    [Abstract] [Full Text] [Related]

  • 16. Estrogen receptor beta (ESR2) polymorphisms in interaction with estrogen receptor alpha (ESR1) and insulin-like growth factor I (IGF1) variants influence the risk of fracture in postmenopausal women.
    Rivadeneira F, van Meurs JB, Kant J, Zillikens MC, Stolk L, Beck TJ, Arp P, Schuit SC, Hofman A, Houwing-Duistermaat JJ, van Duijn CM, van Leeuwen JP, Pols HA, Uitterlinden AG.
    J Bone Miner Res; 2006 Sep 20; 21(9):1443-56. PubMed ID: 16939403
    [Abstract] [Full Text] [Related]

  • 17. Two polymorphisms in the vitamin D receptor gene--association with bone mass and 5-year change in bone mass with or without hormone-replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study.
    Tofteng CL, Jensen JE, Abrahamsen B, Odum L, Brot C.
    J Bone Miner Res; 2002 Aug 20; 17(8):1535-44. PubMed ID: 12162507
    [Abstract] [Full Text] [Related]

  • 18. COL1A1 Sp1 polymorphism predicts perimenopausal and early postmenopausal spinal bone loss.
    MacDonald HM, McGuigan FA, New SA, Campbell MK, Golden MH, Ralston SH, Reid DM.
    J Bone Miner Res; 2001 Sep 20; 16(9):1634-41. PubMed ID: 11547832
    [Abstract] [Full Text] [Related]

  • 19. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis.
    Heilberg IP, Hernandez E, Alonzo E, Valera R, Ferreira LG, Gomes SA, Bellorin-Font E, Weisinger JR.
    Ren Fail; 2005 Sep 20; 27(2):155-61. PubMed ID: 15807179
    [Abstract] [Full Text] [Related]

  • 20. Lack of association between estrogen receptor genotypes and bone mineral density, fracture history, or muscle strength in elderly women.
    Vandevyver C, Vanhoof J, Declerck K, Stinissen P, Vandervorst C, Michiels L, Cassiman JJ, Boonen S, Raus J, Geusens P.
    J Bone Miner Res; 1999 Sep 20; 14(9):1576-82. PubMed ID: 10469287
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.